Apolipoprotein B (ApoB)
Apolipoprotein B represents the total particle concentration of all atherogenic lipoproteins, including LDL, VLDL, IDL, and Lp(a). Because each atherogenic particle carries exactly one molecule of ApoB, it provides the definitive quantification of atherogenic particle burden.
Standard vs. Optimal Reference Rangesmg/dL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
< 90 mg/dL
General reference distribution across unselected commercial populations.
< 60 mg/dL (or < 50 mg/dL in high-risk phenotypes)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
ApoB-100 is an amphipathic structural glycoprotein synthesized by hepatocytes that mediates the clearance and receptor binding of low-density lipoproteins via the LDL receptor (LDLR). Subendothelial retention of ApoB-containing lipoproteins within the arterial intima triggers macrophage phagocytosis, foam cell formation, and the initiation of atherosclerotic plaque.
Differential Diagnosis
Elevated Levels (ApoB High)
- •Familial combined hyperlipidemia
- •Atherogenic dyslipidemia (Metabolic Syndrome)
- •Hypothyroidism (reduced LDLR expression)
- •Insulin resistance and hepatic VLDL overproduction
Low Levels (ApoB Low)
- •Hypobetalipoproteinemia
- •Abetalipoproteinemia
- •Severe hepatic parenchymal dysfunction
- •High-dose PCSK9 inhibitor therapy
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Standard testing requires a 10 to 12 hour overnight fast to minimize postprandial chylomicron interference, although ApoB direct immunoassay is less sensitive to prandial state than calculated LDL-C. Avoid strenuous high-intensity exercise 24 hours prior to blood draw. Serum separator tubes (SST) or EDTA plasma should be centrifuged within 2 hours. High-dose biotin (>5 mg/day) supplementation may interfere with competitive streptavidin-biotin immunoassays, requiring a 48-hour washout period.
Reflexive Testing Protocol:
- Advanced Lipoprotein Particle Quantification (NMR spectroscopy or ion mobility LDL-P)
- Lipoprotein(a) [Lp(a)] baseline evaluation for genetic cardiovascular risk stratification
- Coronary Artery Calcium (CAC) score via non-contrast cardiac CT to evaluate calcified plaque burden
- High-sensitivity C-Reactive Protein (hs-CRP) to assess systemic vascular inflammatory tone
- Carotid intima-media thickness (CIMT) duplex ultrasound to assess subclinical atherosclerosis
Clinical Citations & Primary Literature (1)
- [1]Apolipoprotein B Particles and Risk of Cardiovascular Events - JAMA Cardiology (2022). doi:10.1001/jamacardio.2021.5083
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Apolipoprotein B (ApoB) into overall healthspan optimization.